⌘K

Login Start Free

Home/Filings/4/0001127602-25-001193

4//SEC Filing

Eisele Jeffrey 4

Accession 0001127602-25-001193

CIK 0001492422other

View on SEC.gov Company Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 4:15 PM ET

Size

4.5 KB

Accession

0001127602-25-001193

Insider Transaction Report

Form 4

Period: 2025-01-13

Apellis Pharmaceuticals, Inc.APLS

Chief Development Officer

Transactions

Sale
Common Stock
2025-01-13$28.70/sh−264$7,577→ 56,881 total

Footnotes (1)

[F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 10, 2025.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1

filerCIK 0001827326

Filing Metadata

Form type: 4
Filed: Jan 13, 7:00 PM ET
Accepted: Jan 14, 4:15 PM ET
Size: 4.5 KB

View on SEC.gov